Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT02561273 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT02561273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02561273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Lead sponsor
University of Nebraska
Phase
Phase 1/2
Overall status
Completed
Start date
September 28, 2015
Completion date
November 1, 2020
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, anaplastic large cell lymphoma, alk-positive, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, not otherwise specified, stage ii angioimmunoblastic t-cell lymphoma, stage ii enteropathy-associated t-cell lymphoma, stage iii angioimmunoblastic t-cell lymphoma, stage iii enteropathy-associated t-cell lymphoma, stage iv angioimmunoblastic t-cell lymphoma, stage iv enteropathy-associated t-cell lymphoma